An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Motesanib (Primary) ; Cisplatin; Gemcitabine; Panitumumab
- Indications Cancer
- Focus Adverse reactions
- Sponsors Amgen
- 19 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and efficacy to safety only as reported by ClinicalTrials.gov record.
- 24 Mar 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 24 Mar 2009 Planned end date (Feb 2008) added as reported by ClinicalTrials.gov.